"question:  just speculating what would be the clinical effects of transporting RVX 208 across the BBB.  I'm sure it has "crossed the minds of few folks here" ...

possibly Alzheimers??"

barsax, Would it make any difference seeing that apabetalone had very little to no effect in the BOM clinical trial study as noted below? 

"In the cognitive substudy, 469 participants had test results at baseline, one year and a final visit, which averaged 27 months.  They were split into three groups based on baseline MoCA scores, corresponding to cognitively normal (MoCA of 26 or higher), MCI (22-25), or MCI to AD (below 22). Treatment had no effect in the cognitively normal or MCI groups, whose MoCA scores declined slightly or remained stable.  The 97 participants in the MCI to AD subgroup improved an average of 3 points on the MoCA, compared to one point for placebo. The investigators plan to measure AD biomarkers in plasma samples from the study, to learn if a benefit occurred in AD or vascular dementia, or both"

Koo